Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer
A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients With Resected Adenocarcinoma of the Pancreas
Sponsor: Targovax ASA
Listed as NCT02261714, this PHASE1/PHASE2 trial focuses on Pancreatic Cancer, Resected and remains completed. Sponsored by Targovax ASA, it has been updated 9 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Oct 2019 — Jun 2020 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Targovax ASA
For direct contact, visit the study record on ClinicalTrials.gov .